Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20600198 | 0.85 | PKM (0.65) | DYRK1APKMMAPK1USP2TP53 | |
| SCHEMBL30824206 | 0.85 | PKM (0.65) | DYRK1APKMMAPK1USP2TP53 | |
| SCHEMBL22734642 | 0.85 | MEN1 (0.41) | DYRK1APKMMAPK1MAPTMEN1 | |
| SCHEMBL20621843 | 0.84 | RPS6KB1 (0.43) | DYRK1APKMMAPK1MAPTMEN1 | |
| SCHEMBL29454733 | 0.81 | KMT2A (0.49) | MAPK1USP2TP53MAPTMEN1 | |
| SCHEMBL22118246 | 0.81 | KMT2A (0.49) | MAPK1USP2TP53MAPTMEN1 | |
| SCHEMBL22734620 | 0.80 | PKM (0.61) | DYRK1APKMMAPK1USP2TP53 | |
| SCHEMBL29440759 | 0.80 | PKM (0.61) | DYRK1APKMMAPK1USP2TP53 | |
| SCHEMBL30207740 | 0.80 | PKM (0.68) | DYRK1APKMMAPK1USP2TP53 | |
| SCHEMBL26167968 | 0.80 | PKM (0.68) | DYRK1APKMMAPK1USP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | disclosed |
| CN-114206860-B | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | disclosed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-4255911-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2022117783-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| EP-3980414-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | Elanco Tiergesundheit AG (CH) | 2022-04-13 | — | — | EP | disclosed |
| CN-114206860-A | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | disclosed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | DYRK1A 3320/4885PKM 1513/4885MAPK1 4023/4885 |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, TNNI3 | DYRK1A 3790/4885PKM 1662/4885MAPK1 4012/4885 |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | TBXA2R, PIGS, CYCS | DYRK1A 3320/4885PKM 1513/4885MAPK1 4023/4885 |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | CYCS, FABP3, TNNI3 | DYRK1A 3435/4885PKM 1511/4885MAPK1 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.